This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Teva Pharmaceutical Industries Ltd.
Drug Names(s): Oral transmucosal fentanyl citrate, OT-fentanyl, OTFC, TA-8317, Acref
Description: Actiq is a solid formulation of fentanyl citrate, a potent opioid analgesic, intended for oral transmucosal administration. Fentanyl, a pure opioid agonist, acts primarily through interaction with opioid mu-receptors located in the brain, spinal cord and smooth muscle. The primary site of therapeutic action is the central nervous system (CNS). The most clinically useful pharmacologic effects of the interaction of fentanyl with mu-receptors are analgesia and sedation.
Teva no longer reports for Actiq as of Q3 2011.
Anesta and Abbott
Anesta acquired the rights to Actiq from Abbott in February 2000.
Anesta and Cephalon
Cephalon agreed to a merger on July 17, 2000 under which Cephalon will acquire all of the outstanding shares of Anesta in a tax-free, stock-for-stock transaction intended to be accounted for as a pooling of interests. Under the terms of the merger agreement, Anesta will become a wholly owned subsidiary of Cephalon. Anesta markets ACTIQ for breakthrough cancer pain, and has a highly capable and recently expanded U.S. sales force.
Cephelon and Elan
In October 2002, Cephalon reacquired rights to ACTIQ in twelve countries, principally in Europe, from Elan Pharma International Limited.
Cephalon and Tanabe
In March 2003, Cephalon and Tanabe Seiyaku announced license agreement for Tanabe to commercialize ACTIQ in Japan. As Cephalon's exclusive licensee, Tanabe will develop,...See full deal structure in Biomedtracker
Partners: Perrigo Company PLC Mitsubishi Tanabe Pharma Corporation
Additional information available to subscribers only: